Glioblastoma News and Research

RSS
Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
Johns Hopkins researchers develop lab test that accurately predicts glioblastoma aggression and spread

Johns Hopkins researchers develop lab test that accurately predicts glioblastoma aggression and spread

UCLA scientists develop statistical method for conducting survival analysis of cancer patients

UCLA scientists develop statistical method for conducting survival analysis of cancer patients

Giving chemotherapy after radiotherapy delays rare brain tumour growth

Giving chemotherapy after radiotherapy delays rare brain tumour growth

Radiation therapy with bevacizumab/pembrolizumab improves outcomes in glioma patients

Radiation therapy with bevacizumab/pembrolizumab improves outcomes in glioma patients

Retroviral replicating vector can extend lives of brain cancer patients

Retroviral replicating vector can extend lives of brain cancer patients

Clinical trial to test safety, efficacy of Roswell Park-developed SurVaxM in multiple myeloma patients

Clinical trial to test safety, efficacy of Roswell Park-developed SurVaxM in multiple myeloma patients

Specific immune system genes may determine how long people can live with glioblastoma

Specific immune system genes may determine how long people can live with glioblastoma

Clinical trials of anti-cancer agent PAC-1 continue to progress with anonymous funding

Clinical trials of anti-cancer agent PAC-1 continue to progress with anonymous funding

Mitoxantrone for MS linked to colorectal cancer risk

Mitoxantrone for MS linked to colorectal cancer risk

Investigational drug abemaciclib shows durable clinical activity for variety of cancer types

Investigational drug abemaciclib shows durable clinical activity for variety of cancer types

Small lipid nanocarrier may deliver chemotherapeutic drug more efficiently to brain tumor cells

Small lipid nanocarrier may deliver chemotherapeutic drug more efficiently to brain tumor cells

Umea University researchers find link between vitamin E and brain tumours

Umea University researchers find link between vitamin E and brain tumours

AstraZeneca, MedImmune to provide update on extensive oncology pipeline at ASCO 2016

AstraZeneca, MedImmune to provide update on extensive oncology pipeline at ASCO 2016

Flavopiridol drug could be effective strategy to impair brain cancer growth

Flavopiridol drug could be effective strategy to impair brain cancer growth

Gene therapy shows promise in treating glioblastoma

Gene therapy shows promise in treating glioblastoma

Experimental therapy stops glioblastoma, high-grade gliomas in human cells and mouse models

Experimental therapy stops glioblastoma, high-grade gliomas in human cells and mouse models

Study reveals glioblastoma subtypes tend to develop in different regions of the brain

Study reveals glioblastoma subtypes tend to develop in different regions of the brain

OSMR gene plays key role in driving growth of glioblastoma tumors

OSMR gene plays key role in driving growth of glioblastoma tumors

Scientists derive first molecular model of critical transporter at blood-brain barrier

Scientists derive first molecular model of critical transporter at blood-brain barrier

Scientists examine PD-1-expressing regulatory T cells in aggressive brain cancer

Scientists examine PD-1-expressing regulatory T cells in aggressive brain cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.